1. Home
  2. Analysis

Infusion site discoloration and drugs of ingredients of bumetanide - a phase IV clinical study of FDA data


Summary:

Infusion site discoloration is reported only by a few people who take drugs with ingredients of bumetanide. This phase IV clinical study analyzes 25,323 people who have side effects while taking drugs with ingredients of bumetanide from the the FDA. Among them, 2 have Infusion site discoloration. Find out below who they are, when they have Infusion site discoloration and more.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Bumetanide, Bumex.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jun, 04, 2023

25,323 people reported to have side effects when taking drugs with ingredients of bumetanide.
Among them, 2 people (0.01%) have Infusion site discoloration

What is Infusion site discoloration?

Infusion site discoloration is found to be associated with 318 drugs and 84 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of bumetanide cause Infusion site discoloration?

Conditions people have *:

  1. Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 100.00%
  2. Osteoporosis (bones weak and more likely to break): 2 people, 100.00%
  3. Bladder Disorder: 2 people, 100.00%

Other drugs people take *:

  1. Vitamin D3: 2 people, 100.00%
  2. Vitamin B12: 2 people, 100.00%
  3. Ondansetron: 2 people, 100.00%
  4. Multivitamin: 2 people, 100.00%
  5. Forteo: 2 people, 100.00%
  6. Feraheme: 2 people, 100.00%
  7. Enablex: 2 people, 100.00%
  8. Calcium: 2 people, 100.00%
  9. Baby Aspirin: 2 people, 100.00%

Other side effects people have besides Infusion site discoloration *:

  1. Infusion Site Pain: 2 people, 100.00%
  2. Infusion Site Haemorrhage (bleeding from infusion site): 2 people, 100.00%
  3. Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 2 people, 100.00%

* Approximation only. Some reports may have incomplete information.

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of bumetanide, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on bumetanide. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.